FELIQS Secures $9 Million Series A Funding to Propel FLQ-101 Clinical Program for Retinopathy of Prematurity
TL;DR
FELIQS Corporation secures $9 million Series A funding to advance FLQ-101, offering a competitive edge in treating rare pediatric retinal diseases with its innovative approach.
FELIQS Corporation's FLQ-101, a once-daily oral or intravenous solution, targets retinopathy of prematurity by enhancing retinal vascularization and preventing abnormal neovascularization, with Phase 1b/2 studies starting in 2025.
FELIQS Corporation's breakthrough in pediatric retinal disease treatment with FLQ-101 promises a brighter future for premature infants at risk of blindness, addressing a critical unmet need in neonatal care.
Discover how FELIQS Corporation's FLQ-101, backed by $9 million funding, is set to revolutionize treatment for retinopathy of prematurity, a leading cause of childhood blindness.
Found this article helpful?
Share it with your network and spread the knowledge!
FELIQS Corporation, a biotechnology firm specializing in innovative treatments for rare pediatric retinal diseases, has announced the completion of a $9 million Series A funding round. This financial boost, co-led by a prominent American pharmaceutical company and Beyond Next Ventures Inc., with contributions from the Japan Science and Technology Agency and existing investors, is set to accelerate the clinical development of FLQ-101. FLQ-101 is FELIQS's lead candidate aimed at preventing retinopathy of prematurity (ROP), a condition that poses a significant risk of blindness in premature infants.
The funding will support the Phase 1b/2 tROPhy-1 study of FLQ-101, scheduled to begin in the summer of 2025 in the United States. FLQ-101, which has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), represents a novel approach to treating ROP. It is designed as a once-daily oral or intravenous solution that promotes healthy retinal vascularization while combating inflammation and abnormal blood vessel growth.
Dr. Ken-ichiro (Nobu) Kuninobu, Co-Founder and CEO of FELIQS, expressed gratitude for the investment, highlighting its importance in advancing the company's clinical studies and expanding its pipeline of treatments for pediatric patients. The proceeds from this funding round will be utilized to enhance FELIQS's operational and clinical development teams, expedite key milestones in the U.S. clinical program, and foster collaborative research efforts in the United States.
This development underscores the potential of FLQ-101 to address a pressing unmet medical need in the field of neonatal care, offering hope for improved outcomes for premature infants at risk of ROP. The successful funding round not only validates the scientific and therapeutic promise of FELIQS's approach but also sets the stage for significant advancements in the treatment of rare pediatric retinal diseases.
Curated from Reportable
